Steven Dunn to Antigens, CD
This is a "connection" page, showing publications Steven Dunn has written about Antigens, CD.
Connection Strength
1.017
-
Fierle JK, Brioschi M, de Tiani M, Wetterwald L, Atsaves V, Abram-Saliba J, Petrova TV, Coukos G, Dunn SM. Soluble trivalent engagers redirect cytolytic T?cell activity toward tumor endothelial marker 1. Cell Rep Med. 2021 08 17; 2(8):100362.
Score: 0.672
-
D'Onofrio A, Gano L, Melo R, Mendes F, Oliveira MC, Deno?l T, Schaefer N, Viertl D, Fierle J, Coukos G, Dunn S, Prior JO, Paulo A. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. Eur J Pharm Biopharm. 2021 Jan; 158:233-244.
Score: 0.160
-
Li C, Wang J, Hu J, Feng Y, Hasegawa K, Peng X, Duan X, Zhao A, Mikitsh JL, Muzykantov VR, Chacko AM, Pryma DA, Dunn SM, Coukos G. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget. 2014 Aug 30; 5(16):6994-7012.
Score: 0.104
-
Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, Johnson AD, Brewer JE, Ashfield R, Lissin NM, Jakobsen BK. High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation. Protein Cell. 2010 Dec; 1(12):1118-27.
Score: 0.081